August 23rd - September 2nd

Meet us online at WC11

The 11th World Congress on Alternatives and Animal Use in Life Sciences is the place to be to catch up with the latest developments in the field of 3Rs science. The 3Rs stand for replacement, reduction and refinement in animal studies. This edition of the World Congress will be organized virtually due to continued COVID-19 imposed restrictions, and will be spread over a two-week period, from 23 August to 2 September 2021.

How LifeTec contributes to advancing the 3Rs

LifeTec Group develops and provides state-of-the-art lifelike ex vivo environments making use of slaughterhouse tissue, thus helping to reduce the number of animals that have to be sacrificed solely to test early medical device prototypes or treatments. With innovative and tailored in vitro and ex vivo experiments we help our partners to reach the animal test phase with better insights on their device and on expected outcomes. At WC11 we will be present with two posters, introducing our latest developments on an alternative toxicity model using an ex vivo liver and on a long-term perfusion organ model.

 

Alicia Ruppelt presenting

Latest advancements in BioLiver development

Our new research on the BioLiver platform is focussing on a normothermic perfusion model to successfully perfuse an ex vivo liver obtained from the slaughterhouse for interventional studies and tissue response to drug treatment. The use of fully functional large animal organs gives better translation to humans compared to rodents that are still the gold standard for in vivo experiments, and due to the ex vivo perfusion we can get better and direct insights on tissue response to its treatment.   

This research was funded by European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 860715.

Acknowledgement
SINERGIA
Mattia D'Alessi presenting

Studying prolonged viability of individual organs

As part of the PLS consortium, LifeTec Group is contributing to the development of a bioreactor capable of mimicking the womb. LifeTec Group’s research focuses on how to tackle challenges involving interfacing between fetus and artificial placenta components, such as cannulation, sterility, and blood management. To do this we created an ex vivo organ model that can be used to test these new solutions before proceeding to animal testing.

 

 

This research was funded by Horizon 2020 Framework Programme of the European Union under grant agreement number 863087.

Acknowledgement
Perinatal Life Support

Talk to our engineers!

If you are interested in knowing more about the posters and the research at Lifetec Group, there are two poster sessions where you can talk to our engineers, Alicia Ruppelt and Mattia D’Alessi. In addition, 1-on-1 meetings can also be scheduled outside poster session hours. The posters they will be presenting are:

Alicia Ruppelt: Towards a novel alternative toxicity model with normothermically perfused ex vivo livers based on whole porcine slaughterhouse organs

Mattia D'Alessi: The development of an ex vivo organ model to study prolonged viability of individual organs and evaluate the perinatal life support system prototype

 

Session 1: Friday 27th from 6.00pm to 7.30pm

Session 2: Tuesday 31st from 5.15pm to 6.15pm

 

We will of course remain available after the poster sessions and conference. Don't hesitate to reach out to us via email or phone if you are interested in our research and services!

Head of MedTech Innovation

Marco Stijnen

R&D engineer

Elke van Soest

R&D Engineer

Alicia Ruppelt

R&D Engineer

Mattia D'Alessi

R&D Engineer

Bertus van de Wetering

Leave a message!

©2021 LifeTec Group.  Legal  Credits